BRAF
Serine/threonine-protein kinase B-raf
As of the edition of 20 October 2026, BRAF (serine/threonine-protein kinase B-raf, UniProt P15056) has 22 drugs tested at it and 23 companies on the list, 6 on route A and 7 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P15056
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 138
- Disease areas
- Cancer; Digestive system; Skin and connective tissue; Urinary and reproductive; Pregnancy and women's health; Lungs and airways; Blood and lymph; Hormones
- Registered trials of its drugs
- 1,341
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 6 |
| Active | 6 |
| Went quiet | 5 |
| Stopped | 3 |
| Status not established | 2 |
| Total | 22 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Sorafenib | Marketed | Phase 4 | Ends 2027 |
| Regorafenib | Marketed | Phase 4 | Ends 2032 |
| Dabrafenib | Marketed | Phase 4 | Ends 2030 |
| Vemurafenib | Marketed | Phase 4 | Ends 2030 |
| Encorafenib | Marketed | Phase 4 | Ends 2030 |
| Tovorafenib | Marketed | Phase 3 | Ends 2031 |
| HLX208 | Status not established | Phase 2 | none listed |
| Naporafenib | Active | Phase 3 | none listed |
| Plixorafenib | Active | Phase 2 | none listed |
| Belvarafenib | Active | Phase 2 | none listed |
| ABM-1310 | Stopped | Phase 1 | none listed |
| CEP-32496 | Went quiet | Phase 1 | none listed |
12 of 22 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 6 |
| Route B | 7 |
| Engaged | 6 |
| Undetermined | 4 |
| Total on the list | 23 |
The other 20 companies at BRAF
In the product23 companies in all; 20 are not named here, and no score is.
See the 23 companies at BRAF, ranked, with the facts behind eachRequest access. Nothing is shown until you do.